Anti-Human FGF-23 Reference Antibody (Burosumab, RUO)
- Catalog number: BS10625
- Availability: In Stock
$176.00
- Ex Tax: $176.00
Description: Burosumab (BS10625) is a research-grade recombinant antibody targeting Phosphatonin. Produced in mammalian cells with native-like glycosylation.
Highlights:
• Research Grade — For PK/PD studies, assay development, and ADA research.
• Native Glycosylation — Mammalian expression ensures native-like patterns.
Host species: Human
Isotype: IgG1-kappa
Species reactivity: Human
Immunogen:
Form: Liquid
Storage instructions:
Storage buffer: 0.01M PBS, pH7.4.
Concentration: 1mg/ml
Purity: >95% as determined by SDS-PAGE.
Clonality: Monoclonal
Applications: Research Grade Biosimilar
Target: Phosphatonin,FGF-23,HYPF,FGF23,Fibroblastgrowthfactor23,Tumor-derivedhypophosphatemia-inducingfactor
Purification: Protein A/G purified from cell culture supernatant.
Endotoxin level: <1EU/mg, determined by LAL gel clotting assay
Expression system: Mammalian Cells
Stability and Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names: KRN-23,UX-023,CAS:1610833-03-8
Background: Fibroblast growth factor 23 (FGF23) is a ~27 kDa protein. Regulator of phosphate homeostasis. Inhibits renal tubular phosphate transport by reducing SLC34A1 levels. Up-regulates EGR1 expression in the presence of KL. Acts directly on the parathyroid to decrease PTH secretion. Regulator of vitamin-D metabolism.
References:
1. Unknown (2000) Nature genetics 26, 345-8. PMID: 11062477
2. Bowe, AE. et al. (2001) Biochemical and biophysical research communications 284, 977-81. PMID: 1140989
3. Shimada, T. et al. (2004) Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 19, 429-35. PMID: 15040831
4. Wang, H. et al. (2008) Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 23, 939-48. PMID: 18282132
Note: For research use only. Not suitable for clinical or therapeutic use.
Highlights:
• Research Grade — For PK/PD studies, assay development, and ADA research.
• Native Glycosylation — Mammalian expression ensures native-like patterns.
Host species: Human
Isotype: IgG1-kappa
Species reactivity: Human
Immunogen:
Form: Liquid
Storage instructions:
Storage buffer: 0.01M PBS, pH7.4.
Concentration: 1mg/ml
Purity: >95% as determined by SDS-PAGE.
Clonality: Monoclonal
Applications: Research Grade Biosimilar
Target: Phosphatonin,FGF-23,HYPF,FGF23,Fibroblastgrowthfactor23,Tumor-derivedhypophosphatemia-inducingfactor
Purification: Protein A/G purified from cell culture supernatant.
Endotoxin level: <1EU/mg, determined by LAL gel clotting assay
Expression system: Mammalian Cells
Stability and Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names: KRN-23,UX-023,CAS:1610833-03-8
Background: Fibroblast growth factor 23 (FGF23) is a ~27 kDa protein. Regulator of phosphate homeostasis. Inhibits renal tubular phosphate transport by reducing SLC34A1 levels. Up-regulates EGR1 expression in the presence of KL. Acts directly on the parathyroid to decrease PTH secretion. Regulator of vitamin-D metabolism.
References:
1. Unknown (2000) Nature genetics 26, 345-8. PMID: 11062477
2. Bowe, AE. et al. (2001) Biochemical and biophysical research communications 284, 977-81. PMID: 1140989
3. Shimada, T. et al. (2004) Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 19, 429-35. PMID: 15040831
4. Wang, H. et al. (2008) Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 23, 939-48. PMID: 18282132
Note: For research use only. Not suitable for clinical or therapeutic use.
Images
-
BioactivitySEC-HPLC detection for Research Grade Burosumab.
-
SDS-PAGESDS-PAGE for Research Grade Burosumab.
